For research use only. Not for therapeutic Use.
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].
Angiotensin II is a naturally occurring octapeptide hormone component of the renin-angiotensin-aldosterone system (RAAS) and is a potent vasoconstrictor. Angiotensin II has important roles in cardiovascular, neurologic, and renal physiology, including maintenance of blood pressure, thirst sensation, response to the baroreceptor reflex, determination of renal blood flow and glomerular filtration rate, and electrolyte and free water homeostasis[2].
| Catalog Number | I044309 |
| Synonyms | (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(1S)-1-carboxy-2-(1H-imidazol-5-yl)ethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid;2,2,2-trifluoroacetic acid |
| Molecular Formula | C38H56F3N11O12 |
| Purity | ≥95% |
| InChI | InChI=1S/C36H55N11O10.C2HF3O2/c1-5-19(4)29(34(55)45-26(35(56)57)14-21-16-40-17-42-21)47-32(53)25(13-20-8-10-22(48)11-9-20)44-33(54)28(18(2)3)46-31(52)24(7-6-12-41-36(38)39)43-30(51)23(37)15-27(49)50;3-2(4,5)1(6)7/h8-11,16-19,23-26,28-29,48H,5-7,12-15,37H2,1-4H3,(H,40,42)(H,43,51)(H,44,54)(H,45,55)(H,46,52)(H,47,53)(H,49,50)(H,56,57)(H4,38,39,41);(H,6,7)/t19-,23-,24-,25-,26-,28-,29-;/m0./s1 |
| InChIKey | NHVJMAYWVZIFSD-QRTQXXRZSA-N |
| SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N.C(=O)(C(F)(F)F)O |
| Reference | [1]. Erdös EG, et al. Conversion of angiotensin I to angiotensin II. Am J Med. 1976 May 31;60(6):749-59. [2]. Busse LW, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017;45(8):1285-1294. [3]. Angiotensin II. |
